Swiss pharma sector at risk of US trade investigation
Interpharma warns that Switzerland could face a Section 301 investigation similar to the one launched against Germany. US lawmakers are targeting foreign pricing policies that they claim unfairly shift the costs of pharmaceutical innovation onto American consumers.
X24 PerspectiveRelated Assets:
X24 Perspective